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total plan cost for these agents and the average cost per
prescription for both HMO 1 and HMO 2. In addition,
trend analysis was performed to ascertain if a shift to the
unedited benzodiazepine hypnotics occurred due to the
edit placed by HMO 1. RESULTS: The total number of
prescriptions ﬁlled for zolpidem and zaleplon was 13,783
for HMO 1 vs 15,313 for HMO 2 with total plan costs
of $512,512 for HMO 1 vs $680,689 for HMO 2. The
average cost per prescription for zolpidem was $38.05
and for zaleplon was $26.56 for HMO 1 vs. $44.32 and
$45.63 respectively for HMO 2. Trend analysis demon-
strated no shift in utilization to benzodiazepine hypnotics
for HMO 1. Cost avoidance was calculated by taking 
the difference in average prescription cost, by agent, for
HMO 2 and subtracting the applicable average prescrip-
tion cost for HMO 1. This cost avoided was then multi-
plied by the number of prescriptions ﬁlled, by agent, for
HMO 1, to achieve the total cost avoided. The total cost
avoidance achieved for HMO 1 was nearly $100,000.
CONCLUSION: Appropriate use edits administered by
the Pharmacy Beneﬁts Manager can achieve signiﬁcant
cost avoidance outcomes for HMO clients.
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OBJECTIVE: To concurrently validate three health-
related quality of life (HRQOL) measures in patients with
schizophrenia in Singapore. METHODS: A consecutive
sample of outpatients with schizophrenia seen at a psy-
chiatric hospital completed English or Chinese versions
of the Schizophrenia Quality of Life Scale (SQLS) and the
Short Form 36 Health Survey (SF-36) twice during 2 dif-
ferent visits. At baseline, patients also completed the
Health Utilities Index Mark 3 (HUI3) and were assessed
for psychotic symptoms using a standard checklist. Con-
struct validity was assessed using factor analysis, item-
scale correlation matrix and by examining hypothesized
correlations; reliability using Cronbach’s alpha and 
intraclass correlation coefﬁcients (ICC); and responsive-
ness using Cohen’s effect size measure (d) and paired t-
tests. RESULTS: Baseline and follow-up surveys were
completed by 202 (English-speaking = 140) and 117 sub-
jects respectively (median interval: 25 days). Item-scale
correlation matrix and factor analysis results supported
construct validity of the SQLS. Correlations between the
three measures and psychotic symptoms were generally
as hypothesized (Spearman’s rho: 0.20–0.61, p < 0.01 for
all). Cronbach’s alpha ranged from 0.59 to 0.93 for SQLS
and 0.57 to 0.82 for SF-36 scales. ICCs ranged from 0.46
to 0.82 for SQLS and 0.32 to 0.59 for SF-36 scales. SQLS
psychosocial and SF-36 role-physical, general health,
vitality, social functioning and role-emotional scale scores
improved with improvements in self-reported global
health; SQLS symptoms/side effects and SF-36 social
functioning scale scores worsened with worsening self-
reported global health (effect size: 0.3–0.4, paired t-tests:
p < 0.05 for all). English and Chinese versions of the
SQLS showed similar degrees of construct validity, relia-
bility and responsiveness. CONCLUSIONS: The SQLS,
SF-36 and HUI3 appear to be valid, reliable and respon-
sive (for the SQLS & SF-36) HRQOL measures in out-
patients with schizophrenia in Singapore. Singaporean
English and Chinese versions of SQLS appear to be psy-
chometrically equivalent.
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OBJECTIVE: To assess how subjective tolerability to
medication compares in patients taking ziprasidone or
haloperidol for acute schizophrenia. METHODS: A 6-
week parallel-group, open-label study randomly assigned
555 patients with acute schizophrenia to sequential
IM/oral ziprasidone (<40mg IM for < 3 days, 40 to 
80mg oral thereafter) or haloperidol (<10mg IM for < 3
days, 5 to 20mg oral thereafter). A 10-question Drug
Attitude Inventory (DAI) was administered at random-
ization (baseline), Days 1–3, Week 1, and Week 6 or end-
point. Primary outcome was DAI total score by visit and
change from baseline. Additional outcomes were DAI
subjective positive score, subjective total score, and atti-
tudes/values score. Factor loading and standardized dis-
criminant coefﬁcients were applied. Inferential analyses
were based on main effects ANCOVA. RESULTS:
Patients in the ziprasidone group exhibited statistically
signiﬁcant improvement in subjective tolerability over
patients in the haloperidol group, as measured by DAI
scores: total score after Week 1 (P < 0.01), subjective 
positive score after Week 1 (P < 0.01), and subjective 
total scores after IM therapy (P < 0.05) and Week 1 (P <
0.001). CONCLUSIONS: Patients with acute schizo-
phrenia manifest better feelings about using ziprasidone
than haloperidol, especially at treatment outset (IM phase
through transition to oral dosing). These ﬁndings have
implications for better patient management during acute
exacerbations, for smooth transition from IM to oral
treatment, and for improved compliance with long-term
ziprasidone therapy.
